June 26, 2023
40 high-impact ventures will receive investments from the largest European healthtech venture builder following the successful initial close of its flagship NLC Health Impact Fund.
The NLC Health Impact Fund is the latest and largest fund of NLC to date, established to drive investments in early-stage innovations in healthcare. Following its first close against the 100M target, the Fund will deploy capital towards the first 40 ventures of varied maturity levels, providing initial and follow-on funding.
Hidde Ten Brink, NLC’s Investment Director, commented: “This achievement marks the strong confidence of our investors in NLC’s expertise to leverage opportunities in Europe’s healthtech industry and in its highly selective investment process and track record”.
European healthtech entrepreneurs back NLC’s Health Impact Fund
The funds raised stem entirely from private investors’ capital, reflecting their trust in NLC to make an impact on patients and the healthcare system. The NLC Health Impact Fund grants investors access to a diversified portfolio of ventures in biotech, medtech, green health and digital health.
Europe’s healthcare systems are under mounting pressure as a result of the personnel shortage and growing healthcare demand. Innovation could provide a solution, but due to the lack of early-stage capital investments and expertise too few innovations make it to the market. The NLC Health Impact Fund is aimed at addressing these gaps by providing early-stage capital to the most promising healthcare innovations.
In spite of the headwinds the market is facing, the initial close of the NLC Health Impact Fund exceeded the fund management team’s expectations. Bert Arjan Millenaar, CEO and Founder of NLC, noted: “This proves that the right venture building model, together with NLC’s ecosystem of healthcare stakeholders, can make early-stage healthcare innovations investible again.”
The next close of the NLC Health Impact Fund is expected in September 2023. That will facilitate further investments in another 40 ventures of its portfolio and NLC is optimistic that institutional investors will follow suit, an additional indicator of its successful venture building model.
NLC is a certified B Corp, supports UN Sustainable Development Goals 3, 9, 17, and the fund is SDFR9 compliant. With its growing team of more than 80 professionals and over 100 portfolio ventures built across 11 European countries, NLC is expanding its operations to the US and the Gulf region to invest in early-stage innovations for a sustainable patient impact.
For more information or media requests, please contact Anne Reijns at firstname.lastname@example.org.